GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).
The treatment, which is administered using the company's Ellipta inhaler, is designed to relive symptoms in adult suffers of COPD.
The group said a marketing authoristion application (MAA) for the treatment has been submitted to the European Medicines Agency (EMA).
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Regulatory filings for the product are imminent in the US and planned in other countries during the course of 2013, it added.
The share price was down 0.36% to 1,676p by 11:00 on Friday.
NR
-
Christmas at Chatsworth: review of The Cavendish Hotel at BaslowMoneyWeek Travel Matthew Partridge gets into the festive spirit at The Cavendish Hotel at Baslow and the Christmas market at Chatsworth
-
Tycoon Truong My Lan on death row over world’s biggest bank fraudProperty tycoon Truong My Lan has been found guilty of a corruption scandal that dwarfs Malaysia’s 1MDB fraud and Sam Bankman-Fried’s crypto scam
